Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Henan Cancer Hospital

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Metastatic Breast Cancer

Treatments

Drug: SHR6390

Drug: Fulvestrant

Drug: Famitinib

Study type

Interventional

Funder types

Other

Identifiers

NCT05176080

BC-IIT-FMTN-SHR6390-ET

Details and patient eligibility

About

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.

Full description

This study would enroll patients with hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer, aimed to evaluate the efficacy and safety of treatment with famitinib combined with SHR6390 and endocrine therapy.

Enrollment

46 patients

Sex

Female

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Local recurrent or metastatic breast cancer unsuitable for chemotherapy, confirmed histologically.
HR-positive, HER2- negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
Ib: Patients who received no more than 2 line of chemotherapy in advanced setting were recruited; II: Patients who had not received any chemotherapy and no more than 1 line of endocrine therapy.
18-75 years old.
Eastern Cooperative Oncology Group (ECOG) performance status 0～1.
life expectancy is not less than 12 weeks.
at least one measurable lesion according to RECIST 1.1.
Absolute neutrophil count (ANC) ≥ 1.5×10^9/L, Platelets ≥90×10^9/L, Hemoglobin ≥ 90 g/L; Total bilirubin≤1.5 upper limit of normal (ULN)；Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN (ALT and AST≤5×ULN if liver metastasis); blood urea nitrogen (BUN) and Creatinine (Cr)≤1.5×ULN
Left ventricular ejection fraction (LVEF) ≥ 50% and QTc≤470 ms

Exclusion criteria

Patients who received Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine kinase inhibitors (TKI); II: Patients who received fulvestrant, everolimus or cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor;
Ib: Patients who had symptomatic brain metastasis; II: Patients who had brain metastasis;
Patients unsuitable for endocrine therapy;
Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.
Participated in other drug clinical trials within 4 weeks before admission
Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
Active human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
Has suffered from any heart disease
Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever（> 38.5 ℃） of unknown origin occurs during the screening period/before the first administration.
Researchers believe that patients are unsuitable for any other situation in this study.